REPL Nasdaq

Replimune Group, Inc.

REPL | $6.47 -7.17% -7.73% 870K

(0.0% 1d) (-21.3% 1m) (-62.6% 1y) (0.0% 2d) (-10.5% 3d) (-9.4% 7d) (-23.86% volume)
Earnings Calendar: 2024-02-08
Market Cap: $ 397,178,975
http://www.replimune.com
Sec Filling | Patents | 122 employees

(United States) Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

cancer immunotherapy treatment cancer treatments

add to watch list Paper trade email alert is off

Press-releases

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
REPL | $6.47 -7.17% -7.73% 870K

Health Technology

| -10.35% | O: 3.27% H: 0.13% C: -4.17%
association presentation cancer cell research meeting skin trial results

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
REPL | $6.47 -7.17% -7.73% 870K

Health Technology

| -7.73% | O: 1.72% H: 5.06% C: 3.23%
nasdaq grants

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Published: 2024-03-26 (Crawled : 12:00) - globenewswire.com
REPL | $6.47 -7.17% -7.73% 870K

Health Technology

| -19.88% | O: -0.25% H: 2.49% C: -4.23%
ceo

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
REPL | $6.47 -7.17% -7.73% 870K

Health Technology

| -25.09% | O: 2.9% H: 1.91% C: 1.69%
association cancer research meeting

Replimune to Present at Three Upcoming Investor Conferences - March 5, 2024
Published: 2024-03-05 (Crawled : 17:00) - biospace.com/
REPL | $6.47 -7.17% -7.73% 870K

Health Technology

| -27.36% | O: 0.0% H: 0.79% C: -3.04%

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
Published: 2024-02-08 (Crawled : 13:00) - globenewswire.com
REPL | $6.47 -7.17% -7.73% 870K

Health Technology

| -13.07% | O: 14.56% H: 0.0% C: -9.18%
update financial results

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Published: 2024-01-16 (Crawled : 09:00) - prnewswire.com
COYA | $7.87 -6.75% -7.24% 54K

| 28.41% | O: -2.73% H: 2.64% C: -7.76%
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -12.55% | O: -2.03% H: 0.05% C: 0.05%
SNY | News | $46.32 2.05% 2.01% 3.3M

Health Technology

| -11.59% | O: -1.34% H: 0.0% C: 0.0%
REPL | $6.47 -7.17% -7.73% 870K

Health Technology

| -23.85% | O: -0.83% H: 0.12% C: -4.76%
IMTX | $10.19 -0.68% -0.69% 180K

Health Technology

| -18.65% | O: -1.67% H: 0.08% C: -2.03%
company million pharmaceuticals

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-28 (Crawled : 13:00) - globenewswire.com
REPL | $6.47 -7.17% -7.73% 870K

Health Technology

| -21.25% | O: 0.37% H: 5.35% C: 4.5%
conference